Surrozen (SRZN) Non-Current Deffered Revenue (2020 - 2021)
Surrozen (SRZN) recorded quarterly Non-Current Deffered Revenue of $3.2 million in Q2 2021, little changed quarter-over-quarter from $3.2 million in Q1 2021.
Surrozen (SRZN) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
Surrozen's Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $3.2 million for Q2 2021.
- In Q2 2021, Non-Current Deffered Revenue changed N/A year-over-year to $3.2 million; the TTM figure through Jun 2021 stood at $3.2 million (changed N/A YoY), while the FY2020 annual figure was $3.2 million, changed N/A from the prior year.
- Non-Current Deffered Revenue was $3.2 million for Q2 2021 at Surrozen, roughly flat from $3.2 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $3.2 million in Q4 2020 to a low of $3.2 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 3.22 Mn |
| Mar 31, 2021 | 3.22 Mn |
| Dec 31, 2020 | 3.22 Mn |